| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CBB1007 targets lysine-specific demethylase 1 (LSD1), a histone demethylase that plays a key role in epigenetic regulation. As a substrate-competitive inhibitor, it competes with the histone substrate for binding to the active site of LSD1. This inhibits the demethylation of histone H3 lysine 4 (H3K4) and lysine 9 (H3K9).
|
|---|---|
| ln Vitro |
CBB1007 is a potent and selective inhibitor of LSD1 with an IC50 of 5.27 μM. It preferentially arrests the growth of pluripotent tumors with minimal effect on non-pluripotent cells. CBB1007 promotes the adipogenic differentiation of human embryonic stem cells (hESCs). It also protects cochlear spiral ganglion neurons against cisplatin-induced damage.
|
| ln Vivo |
Specific in vivo activity data for CBB1007 is not extensively detailed in the available literature. As a research compound, its in vivo effects are primarily studied in the context of LSD1 inhibition and its impact on tumor growth, stem cell differentiation, and neuroprotection. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
CBB1007's activity as an LSD1 inhibitor is assessed using in vitro enzyme assays that measure its ability to inhibit LSD1 demethylase activity. The IC50 of 5.27 μM is determined from dose-response curves. Selectivity profiling against other histone demethylases is performed to confirm its specificity.
|
| Cell Assay |
Cellular assays for CBB1007 involve treating cells with the compound and measuring LSD1 activity, histone methylation levels, and gene expression. The compound's effects on cell proliferation, differentiation, and survival are assessed. Its ability to protect neurons from cisplatin-induced damage is evaluated in cellular models.
|
| Animal Protocol |
In vivo animal model protocols for CBB1007 would involve its administration to animal models of cancer, stem cell differentiation, or neurodegeneration. The compound's effects on tumor growth, stem cell differentiation, and neuroprotection would be assessed.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for CBB1007 is not extensively detailed in the available literature. As a small molecule inhibitor with a molecular weight of 534.61, its pharmacokinetic properties would need to be evaluated in preclinical studies. The compound is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
The toxicological profile of CBB1007 has not been extensively characterized. As a research compound, it is intended for research use only and not for human consumption. Standard safety assessments would be required for clinical development.
|
| References | |
| Additional Infomation |
CBB1007 (CAS# 1379573-92-8) is a research compound used to study LSD1 function in epigenetics, cancer, and stem cell biology. It is a potent, reversible, and substrate-competitive LSD1 inhibitor. It is not approved for clinical use and is supplied as a research chemical.
|
| Molecular Formula |
C27H34N8O4
|
|---|---|
| Molecular Weight |
534.6101
|
| Exact Mass |
534.27
|
| CAS # |
1379573-92-8
|
| Related CAS # |
CBB1007 trihydrochloride;2070015-03-9;CBB1007 hydrochloride;2070014-96-7
|
| PubChem CID |
72199289
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
763.8±70.0 °C at 760 mmHg
|
| Flash Point |
415.7±35.7 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.682
|
| LogP |
-2.99
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
921
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])C(C(=O)OC([H])([H])[H])=C([H])C(=C1[H])C([H])([H])N1C([H])([H])C([H])([H])N(/C(=N/[H])/N([H])[H])C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])N(C(C2C([H])=C([H])C(/C(=N/[H])/N([H])[H])=C([H])C=2[H])=O)C([H])([H])C1([H])[H]
|
| InChi Key |
IBVRETRIDAQSEM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H34N8O4/c1-39-26(38)22-15-18(17-32-6-8-35(9-7-32)27(30)31)14-21(16-22)25(37)34-12-10-33(11-13-34)24(36)20-4-2-19(3-5-20)23(28)29/h2-5,14-16H,6-13,17H2,1H3,(H3,28,29)(H3,30,31)
|
| Chemical Name |
methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8705 mL | 9.3526 mL | 18.7052 mL | |
| 5 mM | 0.3741 mL | 1.8705 mL | 3.7410 mL | |
| 10 mM | 0.1871 mL | 0.9353 mL | 1.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
